Compare FRD & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRD | PRQR |
|---|---|---|
| Founded | 1965 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.2M | 262.5M |
| IPO Year | 1995 | 2014 |
| Metric | FRD | PRQR |
|---|---|---|
| Price | $46.09 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 81.8K | ★ 777.2K |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $121,157,278.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | $26.86 | ★ N/A |
| Revenue Growth | ★ 55.82 | N/A |
| 52 Week Low | $16.55 | $1.33 |
| 52 Week High | $48.35 | $3.10 |
| Indicator | FRD | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 69.62 | 65.44 |
| Support Level | $17.68 | $1.94 |
| Resistance Level | N/A | $2.15 |
| Average True Range (ATR) | 2.75 | 0.11 |
| MACD | 0.84 | 0.02 |
| Stochastic Oscillator | 83.42 | 97.67 |
Friedman Industries Inc is a manufacturer and processor of metals and operates in two reportable segments: flat-roll products and tubular products. The flat-roll product segment consists of flat-roll processing facilities located in Hickman, Arkansas; Decatur, Alabama; Miami, Florida; East Chicago, Indiana; Granite City, Illinois and Sinton, Texas and a flat-roll distribution facility located in Orlando, Florida. The tubular product segment consists of the Company's Texas Tubular Products division (TTP) located in Lone Star, Texas. TTP operates two electric resistance welded pipe mills with a combined outside diameter (OD). Its products are flat-roll products and tubular products.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.